Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Recei
Post# of 341
(Total Views: 194)
Posted On: 02/14/2022 3:53:15 PM
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study
- Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technology
- Kernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experience
- CYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://nnw.fm/rdsuf). The approval, granted by the Institution Review Board (“IRB”), gives a green light to a Cybin-sponsored study designed around Kernel’s quantitative neuroimaging technology, Kernel Flow.
“By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and collect quantitative data as opposed to subjective patient reporting,” said Cybin CEO Doug Drysdale. “We believe the results of this study will lead to future studies that will test the effectiveness of psychedelic treatments and will further support our mission to develop psychedelics into therapeutics.”
Early last year, Cybin partnered with Kernel to leverage Kernel’s proprietary Kernel Flow device for psychedelic-based studies and clinical trials (https://nnw.fm/5fikI). The first-of-its-kind device uses quantitative neuroimaging technology to measure brain activity in real time using a wearable helmet during psychedelic treatments. In June 2021, Cybin announced it would be sponsoring a feasibility study of the Kernel Flow technology and ketamine. As part of that sponsorship, Cybin has the rights to any innovations that are discovered or developed through its independent analysis of the study findings. The study received U.S. Food and Drug Administration Investigational New Drug (“IND”) authorization in October 2021, and enrollment is expected to begin in the coming weeks.
“We still have much to learn about what is occurring in the brain during a psychedelic experience,” said Drysdale. “This first-of-its-kind, Cybin-sponsored study using the Kernel Flow device aims to expand our physiological understanding of psychedelic pharmacotherapy. We are excited to be part of this pioneering journey with our partners at Kernel.”
Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information. In contrast with electroencephalography (“EEG”) electrodes that usually require gel on the head or functional magnetic resonance imaging (“fMRI”) studies that require lying in a scanner, the Flow device is a wearable helmet with potential for wide use in neuroscientific or physiological studies of brain activity during psychedelic use. To date, direct neuroimaging research of psychedelic effects is rare and has never been attempted with a wearable device.
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics for a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technology
- Kernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experience
- CYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://nnw.fm/rdsuf). The approval, granted by the Institution Review Board (“IRB”), gives a green light to a Cybin-sponsored study designed around Kernel’s quantitative neuroimaging technology, Kernel Flow.
“By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and collect quantitative data as opposed to subjective patient reporting,” said Cybin CEO Doug Drysdale. “We believe the results of this study will lead to future studies that will test the effectiveness of psychedelic treatments and will further support our mission to develop psychedelics into therapeutics.”
Early last year, Cybin partnered with Kernel to leverage Kernel’s proprietary Kernel Flow device for psychedelic-based studies and clinical trials (https://nnw.fm/5fikI). The first-of-its-kind device uses quantitative neuroimaging technology to measure brain activity in real time using a wearable helmet during psychedelic treatments. In June 2021, Cybin announced it would be sponsoring a feasibility study of the Kernel Flow technology and ketamine. As part of that sponsorship, Cybin has the rights to any innovations that are discovered or developed through its independent analysis of the study findings. The study received U.S. Food and Drug Administration Investigational New Drug (“IND”) authorization in October 2021, and enrollment is expected to begin in the coming weeks.
“We still have much to learn about what is occurring in the brain during a psychedelic experience,” said Drysdale. “This first-of-its-kind, Cybin-sponsored study using the Kernel Flow device aims to expand our physiological understanding of psychedelic pharmacotherapy. We are excited to be part of this pioneering journey with our partners at Kernel.”
Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information. In contrast with electroencephalography (“EEG”) electrodes that usually require gel on the head or functional magnetic resonance imaging (“fMRI”) studies that require lying in a scanner, the Flow device is a wearable helmet with potential for wide use in neuroscientific or physiological studies of brain activity during psychedelic use. To date, direct neuroimaging research of psychedelic effects is rare and has never been attempted with a wearable device.
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics for a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Cybin Inc (CYBN) Stock Research Links
Scroll down for more posts ▼